Novavax (NVAX) said Tuesday that preliminary results from a real-world study showed that its COVID-19 vaccine targeting the JN.1 strain led to fewer and less severe reactogenicity symptoms compared with Pfizer-BioNTech's mRNA 2024-2025 vaccine.
The biotech company said the study, conducted in partnership with the University of Utah Health, showed that the impact of symptoms on daily activities, such as work and family responsibilities, was lower in patients receiving Novavax's vaccine.
Novovax said that, on average, recipients of its vaccine experienced 1.7 symptoms compared with 2.8 systemic symptoms in Pfizer-BioNTech recipients.
Additionally, the company said 43.8% of Pfizer-BioNTech recipients experienced at least one symptom of grade 2 or higher compared with 24.2% of Novavax recipients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.